secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001759425-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M
--------------------------------------------------------------------------

- Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.
- LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.
- 2025 guidance: global net product sales $420-435M with positive cash flow from operations.
- Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.
- Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/0001759425-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer